New Product Release

Proteins for Targeted Bio-Therapeutics

Host Cell Proteins

Recombinant Flu Antigens for Vaccine Strains

Variants and Neutralizing Antibodies for SARS-CoV-2

Proteins for Targeted Bio-Therapeutics

  • ENTPD3: Biomarker for Pancreatic Beta-cells

    Ectonucleoside triphosphate diphosphohydrolase 3 (ENTPD3) is a newly identified biomarker for pancreatic beta cells. Antibodies targeting ENTPD3 may be used for in vivo imaging and live cell sorting of beta-cells.

    Human ENTPD3 10909-H08B
    Purity > 95 %
    Activity Ability to hydrolyze the 5'-phosphate group from the substrate adenosine-5'-triphosphate (ATP)
    Mouse ENTPD3 50269-M08B
  • ULBP2: Regulator of NK Cell Activation

    ULBP2 (UL16 binding protein 2) is one of the ligands for NKG2D. The activation of NKG2D by its ligands, including MICA, MICB, and ULBPs, is an important anti-tumor signaling axis.

    Human ULBP2 12143-H02H 12143-H08H 12143-H27H-B
    Tag hFc His His & AVI
    Anti-Human ULBP2 Monoclonal Antibody
    12143-R022 (Rabbit MAb)
    Immunochemical staining of human ULBP2 in human gastric cancer

HSP70: Stress-induced Chaperon Protein

HSP70 is abnormally upregulated in a variety of cancer cells. It may help the tumor cells to gain resistance to chemotherapy.

  • Species Catalogue Expression Host
    Human 11660-H07H HEK293 Cell
    Human 11660-H07B Insect Cell
    Rat 81955-R07H HEK293 Cell
    Mouse 57562-M07H HEK293 Cell
  • Anti-Human HSP70 Monoclonal Antibody
    11660-R001 (Rabbit MAb)
    Flow cytometric analysis of Human HSPA1A expression on HeLa cells

Other New Products

Molecule Galectin 3 Integrin alpha V beta 3 Integrin alpha V beta 8 Bcl-2
Catalogue 10289-H08H1 CT098-H08H CT099-H08H 10195-H08E1
Tag His His His His

Host Cell Proteins

Chinese Hamster Ovarian (CHO) cell is the most commonly used host organism for recombinant bio-therapeutic production. CHO cells naturally express many types of host cell proteins (HCPs). HCP is known to elicit unwanted immune response against the drug. There is a critical demand in assays and reagents for the detection and quantification of HCPs. Some HCPs, most notably the lipases, are of particular interest because they are hard eliminate. The CHO-expressed PLBL2 (PLBD) and PLA2 proteins can be used as reference materials for HCP assays.

High Purity Recombinant HCPs

Proteins for Influenza Vaccine Strain

Seasonal flu is a common infectious disease of the respiratory tract caused by influenza virus. Vaccination is the most effective way to prevent flu infection. Each year, several different flu strains are selected as vaccine strains based on surveillance data of the recent isolates, and the performance of the vaccines from the previous season. In recent decades, most vaccines are trivalent or quadrivalent, including one H1N1, one H3N2, and the Yamagata and Victoria type flu B.

Vaccine Strain

Sino Biological has newly released a panel of recombinant antigen products covering all WHO-recommended vaccine strains from 2015-2022. These products include HA, NA, and nucleoproteins (NP) and they are designated to be used for a variety of biochemical assays including antibody titer assay, vaccine efficiency assay, and antigenic change assay.

Strains HA NA NP Year
A/Brisbane/02/2018 (H1N1) 40719-V08H 40767-V08B 40776-V08B 2019-2020
A/California/7/2009 (H1N1) 11085-V08B   40205-V08B 2016-2017, 2015-2016
A/Cambodia/e0826360/2020 (H3N2) 40789-V08H
40789-V08H1
40784-V08B 40778-V08B 2021-2022
A/Guangdong-Maonan/SWL1536/2019 (H1N1) 40717-V08H   40723-V08B 2020-2021
A/Hawaii/70/2019 (H1N1) 40717-V08H   40724-V08B 2020-2021
A/Hong Kong/2671/2019 (H3N2) 40721-V08H   40753-V08B 2020-2021
A/Hong Kong/45/2019 (H3N2) 40765-V08H   40754-V08B 2020-2021
A/Hong Kong/4801/2014 (H3N2) 40555-V08B 40569-V08B 40781-V08B 2017-2018, 2016-2017
A/Kansas/14/2017 (H3N2) 40720-V08H 40766-V08B 40779-V08B 2019-2020
A/Michigan/45/2015 (H1N1) 40567-V08H1 40568-V08B 40777-V08B 2018-2019, 2017-2018
A/Singapore/INFIMH-16-0019/2016 (H3N2) 40580-V08H   40779-V08B 2018-2019
A/Switzerland/9715293/2013 (H3N2) 40497-V08B   40499-V08B 2015-2016
A/Victoria/2570/2019 (H1N1) 40787-V08H
40787-V08H1
40785-V08B 40774-V08B 2021-2022
A/Wisconsin/588/2019 (H1N1) 40787-V08H
40787-V08H1
40785-V08B 40774-V08B 2021-2022
B/Brisbane/60/2008 40016-V08B 40203-VNAHC 40783-V08B 2017-2018, 2016-2017
B/Brisbane/60/2008 40016-V08B 40203-VNAHC 40783-V08B 2015-2016
B/Colorado/06/2017 40581-V08H   40782-V08B 2019-2020, 2018-2019
B/Phuket/3073/2013 40498-V08B 40502-V07B 40500-V08B 2020-2021, 2019-2020, 2018-2019, 2017-2018, 2016-2017, 2015-2016
B/Washington/02/2019 40722-V08H 40790-V08B 40755-V08B 2021-2022, 2020-2021

Variants and Neutralizing Antibodies for SARS-CoV-2

SARS-CoV-2 Spike Variants

Several new variants of SARS-COV-2 virus have emerged in recent months. The U.K. variant B.1.1.7, the Brazil variant P.1, the South Africa variant B.1.351 ,and the most recent Indian variant B.1.617 are particular concerning because of their high prevalence. Sino Biological has newly launched RBD and Spike proteins of these variants.

Molecule Lineage Mutations Cat# Tag
RBD B.1.1.7 N501Y 40592-V02H1 Fc
RBD B.1.1.7 N501Y 40592-V08H82 His
RBD B.1.1.7 N501Y 40592-V31H1 rFc
RBD B.1.351 K417N, E484K, N501Y 40592-V08H85 His
RBD B.1.351 E484K 40592-V31H2 rFc
RBD B.1.351 K417N, E484K, N501Y 40592-V31H4 rFc
RBD B.1.351 K417N 40592-V31H6 rFc
RBD B.1.617 L452R, E484Q 40592-V08H88 His
RBD P.1 K417T, E484K, N501Y 40592-V08H86 His
RBD P.1 K417T, E484K, N501Y 40592-V31H5 rFc
RBD P.1 K417T 40592-V31H7 rFc
S1+S2 ECD B.1.1.7 HV69-70 deletion, Y144 deletion, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H 40589-V08B6 His
S1+S2 ECD B.1.351 L18F, D80A, D215G, LAL242-244 deletion, R246I, K417N, E484K, N501Y, D614G, A701V 40589-V08B7 His
S1+S2 ECD B.1.351 D80A, K417N, E484K, N501Y, D614G, A701V 40589-V08B9 His
S1+S2 ECD P.1 L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F 40589-V08B10 His
S1+S2 ECD P.1 L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I 40589-V08B8 His

SARS-CoV-2 Neutralizing Antibodies

Some of the above mutations may have allowed the virus to escape from neutralizing antibodies. To characterize these variants, a new panel of monoclonal antibodies have been launched this month. These antibodies demonstrate differential neutralizing activities against different variants validated by Competitive ELISA Assay. Notably, the B.1.351 and P.1 variants seem to be immune to a subset of the antibodies.

Neutralization Activity by Competitive ELISA Assay
Neutralizing Antibodies WT RBD Recombinant RBD Recombinant S1
B.1.1.7 B.1.351 P.1 B.1.617 B.1.617 B.1.429
40150-D001 ++ + ++ ++ ++ ++ ++
40150-D002 ++ + + ++ ++ ++ ++
40591-MM43 ++ ++ ++ ++ ++ ++ ++
40592-R001 +++ +++ - - +++ +++ +++
40592-R118 +++ +++ - - + + +
40592-R117 +++ +++ - - +++ +++ +++
+: Neutralizing Capacity
The Aforementioned Recombinant RBDs :
WT: 40592-V08B
B.1.1.7 | U.K. Variant: 40592-V08H82 (N501Y)
B.1.351 | South Africa Variant: 40592-V08H85 (K417N, E484K, N501Y)
P.1 | Brazil Variant: 40592-V08H86 (K417T, E484K, N501Y)
B.1.617 | India Variant: 40592-V08H88 (L452R, E484Q)
The Aforementioned Recombinant S1 :
B.1.617 | India Variant: 40591-V08H19 (E154K, E484Q, L452R, D614G, P681R)
B.1.429 | California Variant: 40591-V08H17 (W152C, L452R, D614G)
Please enter your first name! *
Please enter your last name! *
Please enter a valid email address! *
Please enter your company name! *
Please enter your city ! *
Please enter your State/Province ! *
Please enter your country!
*
Receive Sino Biological's News and Production Introduction